-
Security Type
-
Convertible Note
-
Categories
-
Retail, Alcohol, Consumer Goods & Products, Healthcare & Medical, Community & Lifestyle, Health & Fitness
-
Min Investment
-
$250
-
Expected Close Date
-
April 30, 2024
-
Target Raise
-
$50.00K-$1.24M
-
No. Investors
-
221
-
Security Price
-
$1
- Number of Employees
- 6
- Cash
- $1,583,473
- Revenue
- $42,117
- Short Term Debt
- $1,916,588
- Cost of Goods
- $24,239
- Long Term Debt
- $1,550,000
- Net Income
- $-1,764,890
Key Deal Facts
🗝️ Team with decades in innovative technology and scaling businesses from 0-to-1, IPOs & exits
🥇 Early-mover advantage with a category-defining product and a defensible competitive position
🐳 Cannabis is a young, $400 billion global market, and Bud Love fits this entire user base
🚫 NO legal hold-ups. 0% of the difficulties of a cannabis business
💰 The product is entering the market right NOW, w/ gross margin >75% | revenue target of $100M in 2026 (not guaranteed)
💕 Satisfies consumers’ unmet needs - studies show 8/10 consumers preferred cannabis with Bud Love
Management Team / Advisory Board Bios
Roy Lipski CEOEntrepreneur with >25 yrs. experience building companies, including IPOs and acquisitions. Grew small start-up into $500 million company. Ran a public company for close to 10 yrs., Shuchi Sarkar CMOGlobal Marketing Executive for Fortune 500 Brands & Start-ups including HP | Forbes Communications Council | Tech, BioTech, SaaS, B2B/B2C Performance Marketing, Andrew Falconer VP of Commercial DevelopmentSenior sales & BD positions in cannabis for >8 yrs including at Pharmacann, Trucenta, Bellrock Brands, Silverpeak Farms and Americanna. Opened up multiple new states for Mary’s Medicinals., Alastair James COOBreadth of experience from start-ups to large multinationals. COO/Managing Director at UniCredit.
Cambridge University undergraduate; Columbia MBA., Dan Hawksley Fractional CFO Experienced CFO with accountancy and science background. Formerly CFO of GAM’s systematic hedge fund business. 5 yrs. at Deloitte.